Manpreet Saini

Research Associate

UAMS

5 h-index 42 pubs 96 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Manpreet Saini is a Research Associate at the University of Arkansas for Medical Sciences. Their research has focused on comparative studies of patient outcomes and biochemical markers. Recent publications investigate the pattern of lipid profiles in chronic kidney disease patients undergoing conservative management and hemodialysis, and compare lipid profiles in pre-dialysis and post-dialysis end-stage renal disease patients. Saini has also contributed to research on the association of oxidative stress with biochemical markers in diabetic and non-diabetic chronic kidney disease patients. Additionally, their work includes real-world analyses of treatment outcomes and toxicities for various cancer therapies, such as abiraterone vs. enzalutamide in metastatic castration-sensitive prostate cancer, elranatamab and talquetamab in relapsed/refractory multiple myeloma, and meta-analyses comparing induction regimens for multiple myeloma.

Metrics

h-index: 5
Publications: 42
Citations: 96

Positions

Research Associate 2024–present

International Centre for Genetic Engineering and Biotechnology Molecular Medicine ORCID
Research Associate

University of Arkansas for Medical Sciences ORCID
Postdoc Fellow 2022–2024

Emory University Neurosurgery ORCID
Exchange Graduate Student 2020–2023

Emory University Emory Vaccine Center ORCID
Graduate Student 2016–2023

International Center for Genetic Engineering and Biotechnology ICGEB-Emory Vaccine Center ORCID

Selected Publications

POSTER: CT-660: High Specificity but Limited Sensitivity: Is the Khorana Score Sufficient as a Stand-Alone Tool to Guide Thromboprophylaxis in Contemporary Oncological Practice (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
CT-660: High Specificity but Limited Sensitivity: Is the Khorana Score Sufficient as a Stand-Alone Tool to Guide Thromboprophylaxis in Contemporary Oncological Practice (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
MM-561: Dual-Target CAR-T and in Vivo Platforms in Relapsed/Refractory Multiple Myeloma: A Systematic Scoping Review of Efficacy, Toxicity, and Access (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network. (2026)

Journal of Clinical Oncology DOI OpenAlex
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex